Incyte pays out $70M to get hands on Medicxi-backed vitiligo biotech
The M&A wheels keep on turning in biotech — and this time it’s Incyte that gets to do the dealmaking.
The Delaware biotech put out word on Monday morning that it will be shelling out $70 million in cash to acquire Villaris Therapeutics. Incyte will not only acquire Villaris, but also exclusive global rights for Villaris’s lead candidate auremolimab.
Auremolimab, currently in IND-enabling studies, is an anti-IL-15Rβ monoclonal antibody being investigated in vitiligo, with a possibility of other autoimmune and inflammatory indications. Villaris says it is targeting that pathway after a mouse study showed that doing so could be effective at reversing the disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.